From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
Open Access
- 10 October 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 718
- https://doi.org/10.3389/fphar.2017.00718
Abstract
Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumours. Nevertheless, most patients eventually relapse secondary to intrinsic or acquired sunitinib resistance. Autophagy has been reported to contribute to both chemo-sensitivity and -resistance. However, over the last few years, controversial regulatory effects of sunitinib on autophagy have been reported. Since gaining insights into the underlying molecular insights and clinical implications is indispensible for achieving optimum therapeutic response, this minireview article sheds light on the role of a network of prosurvival signaling pathways recently identified as key mediators of sunitinib resistance with established and emerging functions as autophagy regulators. Furthermore, we underscore putative prognostic biomarkers of sunitinib responsiveness that could guide clinicians towards patient stratification and more individualized therapy. Importantly, innovative therapeutic strategies/approaches to overcome sunitinib resistance both evaluated in preclinical studies and perspective clinical trials are discussed which could ultimately be translated to better clinical outcome.Keywords
This publication has 70 references indexed in Scilit:
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma PatientsClinical Cancer Research, 2012
- Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer CellsMolecular Cancer Therapeutics, 2012
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapyInternational Immunopharmacology, 2011
- Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinomaInvestigational New Drugs, 2010
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft StudyMolecular Cancer Therapeutics, 2010
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling PathwaysMolecular Cancer Research, 2010
- Phase II study of sunitinib in men with advanced prostate cancerAnnals of Oncology, 2009
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2Drug Metabolism and Disposition, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007